Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNBX PharmaceuticalsCNBX +33.33% Current Ratio is 0.00 as of May. 2026. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, CNBX Pharmaceuticals ranks worse than 70871.65% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. CNBX Pharmaceuticals's current ratio for the quarter that ended in May. 2026 was 0.00.
CNBX Pharmaceuticals has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If CNBX Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for CNBX Pharmaceuticals's Current Ratio or its related term are showing as below:
During the past 13 years, CNBX Pharmaceuticals's highest Current Ratio was 17.53. The lowest was 0.01. And the median was 0.71.
CNBX's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.91 * Ranked among companies with meaningful Current Ratio only.
CNBX Pharmaceuticals (OTCPK:CNBX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
CNBX Pharmaceuticals Current Ratio Related Terms
CNBX Pharmaceuticals Current Ratio Historical Data
* Premium members only.
The historical data trend for CNBX Pharmaceuticals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNBX vs SIGY, LIPO, CARM: Current Ratio Comparison
For the Biotechnology subindustry, CNBX Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CNBX Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where CNBX Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNBX Pharmaceuticals (CNBX) has a Current Ratio of 0.00 as of May. 2026. Over the past decade, CNBX Pharmaceuticals' Current Ratio has ranged from 0.01 to 17.53. According to the industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 1411 companies in the Biotechnology industry.
Is CNBX Pharmaceuticals' Current Ratio too high?
CNBX Pharmaceuticals' current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 17.53. Based on the distribution chart, CNBX Pharmaceuticals ranks #999999 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CNBX Pharmaceuticals' Current Ratio compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #999999 out of 1411 companies for Current Ratio. This places CNBX Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.91. Historically, CNBX Pharmaceuticals' own Current Ratio has ranged from 0.01 to 17.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CNBX Pharmaceuticals's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Current Ratio of 0.00. The current Current Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Current Ratio is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNBX has been successfully added to your 
